Binx and UPS Healthcare pair advanced infectious disease testing with superior global logistics to reach populations everywhere, starting in the United Kingdom

Study signals “real paradigm shift” in care resulting from the world’s first FDA-cleared, 30-minute, molecular point-of-care platform for the detection of chlamydia and gonorrhea

Latest FDA clearance establishes binx as the fastest dual-gender rapid test-and-treat platform for chlamydia and gonorrhea

COVID-19 pandemic has created growing backlog of millions in need of routine STI testing

binx health was featured in Fortune Magazine highlighting the io platform as not only the first and fastest FDA-cleared molecular point-of-care diagnostic for the detection of chlamydia and gonorrhea, but…

binx offers first FDA 510(k) cleared molecular point-of-care solution for test and treat of sexually-transmitted infections in a single visit

binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that Jeffrey Luber, president and CEO is scheduled to present on Thursday, November 21, 2019 at 11:00…

binx FDA-cleared platform already impacting human health—poised to transform care for millions

binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)

binx health, the pioneer in anywhere care in women’s health, today announced the appointment of Dr. Gail Marcus to its Board of Directors.